Stem Cell Transplant Trumps Fingolimod for RRMS Relapse Risk Stem Cell Transplant Trumps Fingolimod for RRMS Relapse Risk
Autologous hematopoietic stem cell transplantation is linked to significantly lower relapse rates than fingolimod in patients with relapsing-remitting multiple sclerosis. But adverse events are common.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - October 27, 2022 Category: Transplant Surgery Tags: Neurology & Neurosurgery News Source Type: news

Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)Nine-year safety data for OCREVUS reinforces itsfavourable benefit-risk profileNew research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSDBasel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) ...
Source: Roche Media News - October 19, 2022 Category: Pharmaceuticals Source Type: news

Roche to present new OCREVUS (ocrelizumab) data in multiple sclerosis and continued research into neuromyelitis optica spectrum disorder at ECTRIMS 2022
OCREVUS data will show significant benefit on slowing disease activity and progression in patients with treatment-naive early-stage relapsing-remitting multiple sclerosis (RRMS)Largest pregnancy safety data across anti-CD20 medicines for OCREVUS in multiple sclerosis (MS)Nine-year safety data for OCREVUS reinforces itsfavourable benefit-risk profileNew research demonstrates impact of misdiagnosis and delay of starting treatment in NMOSDBasel, 19 October 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new OCREVUS ® (ocrelizumab) data and continued research into neuromyelitis optica spectrum disorder (NMOSD) ...
Source: Roche Investor Update - October 19, 2022 Category: Pharmaceuticals Source Type: news

Rituximab Trumps Natalizumab in MS Relapse Rituximab Trumps Natalizumab in MS Relapse
Although rituximab was consistently linked to better relapse outcomes vs natalizumab in new research, outcomes did not differ between dimethyl fumarate and fingolimod.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 3, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Rituximab Better Than Natalizumab for MS Relapses? Rituximab Better Than Natalizumab for MS Relapses?
Although rituximab was consistently linked to better relapse outcomes vs natalizumab in new research, outcomes did not differ between dimethyl fumarate and fingolimod.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - December 3, 2021 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

COVID-19 Vax in MS: Lower Response on Certain Medications COVID-19 Vax in MS: Lower Response on Certain Medications
New data on COVID vaccination in MS patients has shown a reduced humoral response in patients treated with certain medications -- including ocrelizumab, rituximab, and fingolimod -- but not others.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 14, 2021 Category: Infectious Diseases Tags: Neurology & Neurosurgery News Source Type: news

Zydus Cadila gets tentative USFDA nod to market generic sclerosis treatment drug
Drug firm Zydus Cadila on Thursday said it has received tentative approval from the US health regulator to market Fingolimod capsules, used in the treatment of multiple sclerosis, in the American market. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 24, 2021 Category: Pharmaceuticals Source Type: news

FDA investiga infecci ón cerebral poco común en paciente que tomó Gilenya (fingolimod)
[8/29/2013] La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) alertando al público que un paciente en Europa con diagnóstico de esclerosis múltiple contrajo una infección cerebral poco común pero seria, después de tomar el medicamento Gilenya (fingolimod). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Comunicado de la FDA sobre la seguridad de los medicamentos: Recomendaciones modificadas para observaci ón cardiovascular y uso del medicamento Gilenya (fingolimod) para la esclerosis múltiple
El lunes, 14 de mayo del 2012, la Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) anunció que ha concluido su evaluación de un informe sobre un paciente que murió después de la primera dosis del medicamento Gilenya (fingolimod) para la esclerosis múltiple. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 17, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Highlights on Treatment of Progressive MS From ECTRIMS 2020 Highlights on Treatment of Progressive MS From ECTRIMS 2020
Dr Mark Freedman reports on key findings in progressive MS from ECTRIMS 2020, including use of first-in-class TKI masitinib, risk for fingolimod-related PML, and a prognostic marker for disability.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 14, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Safety Concern With Fingolimod to Ocrelizumab Switch in MS Safety Concern With Fingolimod to Ocrelizumab Switch in MS
A new study has suggested that some patients who make this switch may experience"double immunosuppression" – very low levels of both T and B cells, and therefore be at increased risk for infection.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - September 21, 2020 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news

Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed Optimal Dose of Fingolimod for Multiple Sclerosis Confirmed
The 0.5-mg dose of fingolimod provides a greater reduction in annualized relapse rate vs both the 0.25-mg dose of fingolimod and the 20-mg dose of glatiramer acetate.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 17, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Multiple Sclerosis Drug Shows Promise For HIV Prevention And Treatment
Researchers at The George Washington University in D.C. and their colleagues found that a drug called Fingolimod, that is approved for multiple sclerosis treatment, also blocks HIV transmission and infection in human cells. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 13, 2020 Category: Pharmaceuticals Authors: Anuradha Varanasi, Contributor Tags: Healthcare /healthcare Innovation /innovation Source Type: news

Multiple sclerosis drug blocks HIV infection and transmission in human immune cells
(PLOS) An immunomodulatory drug called fingolimod, which is approved for the treatment of multiple sclerosis, blocks human immunodeficiency virus (HIV) infection and transmission in human immune cells, according to a study published August 13 in the open-access journal PLOS Pathogens by Postdoctoral Fellow Rachel Resop and Assistant Professor Alberto Bosque of The George Washington University, and colleagues. These preliminary findings suggest that this compound may be a promising novel therapy for HIV treatment and prevention. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 13, 2020 Category: Infectious Diseases Source Type: news

Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules
"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation," the drug major said in a filing to BSE. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 18, 2020 Category: Pharmaceuticals Source Type: news